IRIS
LAPADULA, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.547
EU - Europa 2.409
AS - Asia 1.276
SA - Sud America 12
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 16.268
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.527
CN - Cina 847
SE - Svezia 693
FR - Francia 410
SG - Singapore 339
IT - Italia 311
DE - Germania 304
FI - Finlandia 203
UA - Ucraina 176
GB - Regno Unito 164
BE - Belgio 51
IE - Irlanda 48
IN - India 25
VN - Vietnam 24
CA - Canada 16
IR - Iran 16
CZ - Repubblica Ceca 9
EU - Europa 8
RU - Federazione Russa 8
BR - Brasile 7
AU - Australia 6
NL - Olanda 6
AT - Austria 5
EG - Egitto 5
CL - Cile 4
CH - Svizzera 3
ES - Italia 3
HK - Hong Kong 3
HR - Croazia 3
ID - Indonesia 3
LT - Lituania 3
RO - Romania 3
TR - Turchia 3
JP - Giappone 2
MN - Mongolia 2
MX - Messico 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
BO - Bolivia 1
BW - Botswana 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
IL - Israele 1
KE - Kenya 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MP - Marianne Settentrionali, isole 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 16.268
Salva come PNG Salva come JPEG
Città #
Fairfield 1.879
Woodbridge 1.472
Houston 1.179
Chandler 1.058
Ashburn 842
Seattle 791
Ann Arbor 748
Cambridge 682
Wilmington 604
Nyköping 544
Jacksonville 531
Lawrence 244
Roxbury 244
Singapore 229
Nanjing 222
Beijing 183
Des Moines 148
Inglewood 144
Princeton 136
New York 133
Boardman 95
Bari 90
San Diego 85
Dearborn 81
Shenyang 65
Santa Clara 56
Brussels 51
Hebei 50
Paris 49
Dublin 48
Nanchang 43
London 41
Jiaxing 39
Redwood City 35
Changsha 31
Tianjin 31
Brooklyn 23
Dong Ket 23
Los Angeles 23
Munich 23
Guangzhou 20
Hefei 18
Helsinki 18
Jinan 16
Augusta 13
San Mateo 13
Kunming 12
Pune 12
Ardabil 10
Durham 10
San Francisco 10
Toronto 10
Washington 10
Detroit 9
Indiana 9
Leawood 9
Norwalk 9
Shanghai 9
Zhengzhou 9
Chicago 8
Kilburn 8
Milan 8
Prescot 8
Wuhan 7
Taizhou 6
Tappahannock 6
Triggiano 6
Auburn Hills 5
Brno 5
Monmouth Junction 5
New Delhi 5
Vienna 5
Cairo 4
Edinburgh 4
Frankfurt am Main 4
Gallarate 4
Grafing 4
Hounslow 4
Islington 4
Ottawa 4
Acton 3
Canberra 3
Capiago Intimiano 3
Gloucester 3
Grumo Appula 3
Jinhua 3
Konstanz 3
Mumbai 3
Ningbo 3
Oberursel 3
Shaoxing 3
Simi Valley 3
Wiesbaden 3
Cerignola 2
Cerveteri 2
Chongqing 2
Fuzhou 2
Genoa 2
Groningen 2
Haikou 2
Totale 13.388
Salva come PNG Salva come JPEG
Nome #
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 140
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 131
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 126
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 123
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 121
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan 120
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. 115
Early changes of articular cartilage, synovial membrane and subchondral bone in an experimental model of goat osteoarthrtitis 113
Papular-purpuric gloves and socks syndrome due to parvovirus B19: a report of two simultaneous cases in cohabitant families 113
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 111
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine 111
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 110
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 109
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 109
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 109
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 107
Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies 105
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 104
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab 104
PRESENT STATUS AND NEW PERSPECTIVES IN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THERAPY 104
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features 104
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 103
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 103
Management of Small Vessel Vasculitides 102
null 101
ASSOCIATION OF SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS: A CASE REPORT 100
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 100
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 100
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 99
Old and new antirheumatic drugs and the risk of hepatotoxicity 98
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 97
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 97
Adalimumab in the treatment of immune-mediated diseases 97
null 97
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: A multicenter randomized clinical trial 97
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 96
Orofacial Manifestations and Temporomandibular Disorders of Sjogren Syndrome: An Observational Study 96
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 95
Serum amyloid-A in Behçet's disease 94
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 94
Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis 93
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature 93
Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA 93
Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study 93
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 93
Untangling the web of systemic autoinflammatory diseases 92
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 92
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 92
AN UNWELCOME HOST IN THE PATHOGENESIS OF ARTHRITIDES 90
Obesity and Inflammation – Targets for OA Therapy 90
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 90
Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid 89
ISOLATED STERNOCLAVICULAR JOINT ARTHRITIS IN HEROIN ADDICTS AND/OR HIV POSITIVE PATIENTS: THREE CASES 89
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 89
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register) 88
Sarcoidosis presenting with Raynaud's syndrome: a case report 87
Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations 87
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 87
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 87
PHENOTYPING OF CHONDROCYTES FROM HUMAN OSTEOARTHRITIC CARTILAGE: CHONDROCYTE EXPRESSION OF BETA INTEGRINS AND CORRELATION WITH ANATOMIC INJURY 86
null 86
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 86
Isolated thrombocytopenia associated with low dose methotrexate therapy 85
null 85
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies 85
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 84
null 84
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 84
Prevalence of anti-CCP antibodies in systemic sclerosis 84
null 84
Intra-articular therapy with tumor necrosis factor-α antagonists: An update 83
Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database 83
null 83
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 83
null 82
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 82
null 82
null 82
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 81
The pathophysiology of osteoarthritis 80
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 80
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 80
null 79
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry 78
null 78
Laser-evoked potentials habituation in fibromyalgia 77
Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan) 76
CHONDROCYTES-ECM INTERACTIONS IN HUMAN OSTEOARTHRITIS In: Mallia C., Uitto J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA 76
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 76
MONOCLONAL ANTIBODY INVESTIGATION IN RHEUMATOID ARTHRITIS: PRESENCE OF A T CELL SUBPOPULATION BEARING A DOUBLE MARKER 75
null 75
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: Meeting rheumatologists' requirements in routine clinical practice 75
THE INHIBITOR OF COSTIMULATION OF T CELLS: ABATACEPT 75
Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations 75
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 74
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 74
Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset 73
null 73
null 73
null 73
Totale 9.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.863
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.863
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.289 0 0 0 0 497 470 530 501 577 256 322 136
2020/20212.468 181 228 181 105 403 140 207 233 193 284 169 144
2021/20221.791 125 208 23 110 87 118 85 102 101 111 292 429
2022/20232.788 432 322 191 262 318 356 58 286 446 19 59 39
2023/2024756 76 174 32 55 48 176 17 43 3 33 12 87
2024/2025618 63 64 340 103 48 0 0 0 0 0 0 0
Totale 16.904